Keros Therapeutics Inc held its 2025 Annual Meeting of Stockholders on June 9, 2025. During the meeting, stockholders expressed significant concern about the Board's capital allocation decisions. Proposals included a call for the company to return $475 million to stockholders through a special dividend by the end of Q3 2025, which was not approved. Additionally, there was a proposal for implementing a contingent value right related to the Takeda partnership by year-end, which was also not approved. Significant withhold votes were recorded against directors Mary Ann Gray and Alpna Seth, reflecting a demand for change and a more disciplined capital allocation strategy.